scholarly journals Preventive and Therapeutic Effects ofAnisakis simplexLarval Protein in a Mouse Model of Crohn'S Disease

2013 ◽  
Vol 28 (2) ◽  
pp. 107
Author(s):  
Hee-Jae Cha ◽  
Mee Sun Ock
2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Elodie Gimier ◽  
Mélissa Chervy ◽  
Allison Agus ◽  
Adeline Sivignon ◽  
Elisabeth Billard ◽  
...  

2021 ◽  
Vol 12 (9) ◽  
Author(s):  
Fan Zhao ◽  
Tao Zheng ◽  
Wenbin Gong ◽  
Jie Wu ◽  
Haohao Xie ◽  
...  

AbstractCrohn’s disease (CD) is an intestinal immune-dysfunctional disease. Extracellular vesicles (EVs) are membrane-enclosed particles full of functional molecules, e.g., nuclear acids. Recently, EVs have been shown to participate in the development of CD by realizing intercellular communication among intestinal cells. However, the role of EVs carrying double-strand DNA (dsDNA) shed from sites of intestinal inflammation in CD has not been investigated. Here we isolated EVs from the plasma or colon lavage of murine colitis and CD patients. The level of exosomal dsDNA, including mtDNA and nDNA, significantly increased in murine colitis and active human CD, and was positively correlated with the disease activity. Moreover, the activation of the STING pathway was verified in CD. EVs from the plasma of active human CD triggered STING activation in macrophages in vitro. EVs from LPS-damaged colon epithelial cells were also shown to raise inflammation in macrophages via activating the STING pathway, but the effect disappeared after the removal of exosomal dsDNA. These findings were further confirmed in STING-deficient mice and macrophages. STING deficiency significantly ameliorated colitis. Besides, potential therapeutic effects of GW4869, an inhibitor of EVs release were assessed. The application of GW4869 successfully ameliorated murine colitis by inhibiting STING activation. In conclusion, exosomal dsDNA was found to promote intestinal inflammation via activating the STING pathway in macrophages and act as a potential mechanistic biomarker and therapeutic target of CD.


2009 ◽  
Vol 8 (4) ◽  
pp. 2045-2057 ◽  
Author(s):  
Hui-Ming Lin ◽  
Shelley J. Edmunds ◽  
Nuala A. Helsby ◽  
Lynnette R. Ferguson ◽  
Daryl D. Rowan

2019 ◽  
Vol 2019 ◽  
pp. 1-7
Author(s):  
Zi-qi Yu ◽  
Wen-fei Wang ◽  
Chuan-zhi Zhu ◽  
Ke-hong Zhang ◽  
Xin-chun Chen ◽  
...  

Background. Because of the similarity of intestinal tuberculosis and Crohn’s disease in disease phenotype, differential diagnosis has always been a clinical problem. Arachidonic acid metabolites play an important role in the inflammatory response of intestinal tuberculosis and Crohn’s disease. Recent studies have shown that the polymorphism locus in the promoter region of LTA4H gene affects LTB4 expression level and the susceptibility to extrapulmonary tuberculosis. Thus, we identified a total of 148 patients with intestinal tuberculosis, 145 with Crohn’s disease, and 700 normal controls in this study. Methods. All the study participants were local Han people from Jiangxi Province in the past eleven years. DNA was extracted from the paraffin-embedded specimens or the whole blood. The LTA4H promoter SNP (rs17525495) was genotyped with TaqMan assay. Results. The T-alleles frequency was not significantly increased in patients with intestinal tuberculosis compared with healthy control group (p=0.630; OR=1.07; 95%CI=0.81-1.41), while patients with Crohn’s disease have significantly increased T allele frequency compared with healthy population (p=0.032; OR=1.34; 95%CI=1.03-1.75). During treatment, the presence of the T allele significantly increased the proportion of Crohn’s patients requiring glucocorticoids (p<0.05). Conclusions. The T allele of LTA4H gene SNP (rs17525495) is a risk factor for Crohn’s disease instead of intestinal tuberculosis. More importantly, there may be a potential association of the different genotypes of rs17525495 with the treatment efficacy of 5-ASA and glucocorticoids in patients with Crohn’s disease. The association between LTA4H polymorphism and drugs therapeutic effects might contribute to the practice of precision medicine and the prediction of clinical outcomes.


2003 ◽  
Vol 124 (4) ◽  
pp. 961-971 ◽  
Author(s):  
Catalina Abad ◽  
Carmen Martinez ◽  
Maria G. Juarranz ◽  
Alicia Arranz ◽  
Javier Leceta ◽  
...  

2016 ◽  
Vol 1 (3) ◽  
pp. eaaf8864-eaaf8864 ◽  
Author(s):  
Bernard C. Lo ◽  
Matthew J. Gold ◽  
Michael R. Hughes ◽  
Frann Antignano ◽  
Yanet Valdez ◽  
...  

2018 ◽  
Vol 119 (8) ◽  
pp. 6743-6755 ◽  
Author(s):  
Suncica Buljevic ◽  
Dijana Detel ◽  
Ester P. Pugel ◽  
Jadranka Varljen

Author(s):  
Hajime Tanaka ◽  
Sivagami Gunasekaran ◽  
Dina Mourad Saleh ◽  
William Theodore Alexander ◽  
David Bedell Alexander ◽  
...  

Both ulcerative colitis and colonic Crohn's disease patients have a significantly increased risk of developing colorectal cancer. bLF is reported to inhibit the development of colon cancer in rats and mice, and in a placebo controlled trial, ingestion of bLF inhibited the growth of intestinal polyps. In addition, in a case study a Crohn's disease patient was reported to have remained in remission for over 7 years while ingesting 1 gram of bLF daily. Thus, bLF has an inhibitory effect on colon carcinogenesis, and it may also promote remission of Crohn's disease. The purpose of the present study was to begin to investigate the effect of bLF on a mouse model of IBD-related colorectal cancer. Azoxymethane (AOM) was used to initiate intestinal cancer and dextran sulfate sodium (DSS) was used to induce IBD-like inflammation in the intestine of C57BL/6 mice. Mice were divided into 4 groups: untreated, bLF alone, AOM+DSS, and AOM+DSS+bLF. At the end of the study, mice given AOM+DSS+LF had a better fecal score, less wounding in the colon, and less weight loss than mice in the AOM+DSS group. However, there were no statistically significant differences between the two groups in tumor burden.


Sign in / Sign up

Export Citation Format

Share Document